

## CLAIMS

1. A cholangiocarcinoma cell growth inhibitor comprising an anti-glypican-3 antibody.
2. The cholangiocarcinoma cell growth inhibitor as claimed in claim 1, wherein the anti-glypican-3 antibody has a cytotoxic activity.
3. The cholangiocarcinoma cell growth inhibitor as claimed in claim 2, wherein the cytotoxic activity is an antibody-dependent cytotoxic (ADCC) activity or a complement-dependent cytotoxic (CDC) activity.
4. The cholangiocarcinoma cell growth inhibitor as claimed in claim 1, wherein the anti-glypican-3 antibody is an antibody having a cytotoxic substance attached thereto.
5. The cholangiocarcinoma cell growth inhibitor as claimed in any one of claims 1 to 4, wherein the antibody is a monoclonal antibody.
6. The cholangiocarcinoma cell growth inhibitor as claimed in any one of claims 1 to 4, wherein the antibody is a humanized or chimera antibody.
7. A diagnostic agent for cholangiocarcinoma comprising an anti-glypican-3 antibody.
8. The diagnostic agent for cholangiocarcinoma as claimed in claim 7 comprising an anti-glypican-3 antibody immobilized on a support and an antibody labeled with a labeling

substance.

9. The diagnostic agent for cholangiocarcinoma as claimed in claim 7 or 8, wherein the antibody is a monoclonal antibody.

10. A diagnostic kit for diagnosis of cholangiocarcinoma comprising an anti-glypican-3 antibody.

11. The diagnostic kit for diagnosis of cholangiocarcinoma as claimed in claim 10 comprising an anti-glypican-3 antibody immobilized on a support and an antibody labeled with a labeling substance.

12. A method for inhibiting the growth of cholangiocarcinoma cells comprising administering an anti-glypican-3 antibody to a patient suffered from cholangiocarcinoma.

13. A method for diagnosing cholangiocarcinoma comprising detecting a glypican-3 protein in an assay sample.